Neuvasq presented new data at EBBM

Neuvasq was pleased to have been selected for an oral presentation at the annual European Brain Barriers Meeting that took place in Bern on September 8-10.

Sylvaine Guérit, Head of Preclinical Research, had the opportunity to present new efficacy data for Neuvasq’s lead candidate Ab NVQ401, a bispecific antibody that activates the Wnt/beta-catenin signaling pathway, in several established animal models of retinopathy.

“I was really excited to be able to present our results and share thoughts about our project with experts” says Sylvaine.